Form D · Biotechnology

ALUMIS INC.

South San Francisco, CA · CIK 0001847367

Offering snapshot reported Jul 24, 2024 · SEC filing

Reported sold
$40M
Offering amount: $40M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 17, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 24, 2024Initial$40,000,000No comparison1SEC filing
Mar 11, 2024Initial$129,499,957No comparison24SEC filing
Mar 19, 2021Initial$60,000,000No comparison3SEC filing
Feb 25, 2021Initial$10,500,000No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-519656

Source: Form D, filed Jul 24, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Srinivas Akkaraju Director
Martin Babler Director, Executive
Vikram Bajaj Director
Julian Baker Director
Mark Bradley Executive
Alan B. Colowick Director
Jorn Drappa Executive
Richard Gaster Director
David M. Goldstein Executive
Roy C. Hardiman Executive
Sara Klein Executive
June Lee Director, Executive
Patrick Machado Director
Derrick Richardson Executive
Michael Rome Director
John R. Schroer Executive
Sapna B. Srivastava Director
James B. Tananbaum Director
Zhengbin Yao Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
280 East Grand Avenue
South San Francisco, CA, 94080